Teachers Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 45.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,005,728 shares of the biopharmaceutical company’s stock after purchasing an additional 936,087 shares during the period. Teachers Advisors LLC owned 0.23% of Gilead Sciences worth $212,745,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of GILD. RNC Capital Management LLC boosted its position in Gilead Sciences by 7.2% during the first quarter. RNC Capital Management LLC now owns 82,517 shares of the biopharmaceutical company’s stock valued at $5,605,000 after purchasing an additional 5,510 shares during the last quarter. Underhill Investment Management LLC boosted its position in Gilead Sciences by 98.7% during the first quarter. Underhill Investment Management LLC now owns 168,800 shares of the biopharmaceutical company’s stock valued at $11,465,000 after purchasing an additional 83,850 shares during the last quarter. Intrust Bank NA boosted its position in Gilead Sciences by 3.4% during the first quarter. Intrust Bank NA now owns 14,177 shares of the biopharmaceutical company’s stock valued at $963,000 after purchasing an additional 464 shares during the last quarter. Ropes Wealth Advisors LLC boosted its position in Gilead Sciences by 41.1% during the first quarter. Ropes Wealth Advisors LLC now owns 9,731 shares of the biopharmaceutical company’s stock valued at $661,000 after purchasing an additional 2,836 shares during the last quarter. Finally, Morningstar Investment Services LLC boosted its position in Gilead Sciences by 99.3% during the first quarter. Morningstar Investment Services LLC now owns 55,564 shares of the biopharmaceutical company’s stock valued at $3,774,000 after purchasing an additional 27,683 shares during the last quarter. 76.30% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Teachers Advisors LLC Boosts Position in Gilead Sciences, Inc. (GILD)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/11/20/teachers-advisors-llc-boosts-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences, Inc. (GILD) opened at $72.44 on Monday. The stock has a market capitalization of $94,626.13, a P/E ratio of 7.56, a PEG ratio of -1.21 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the prior year, the business earned $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.87%. Gilead Sciences’s payout ratio is 23.69%.

GILD has been the subject of a number of recent analyst reports. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Thursday, August 31st. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 price objective on shares of Gilead Sciences in a research report on Thursday, August 31st. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a research report on Friday, October 13th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $85.00 price objective (up from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $84.87.

In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $83.11, for a total value of $6,094,705.63. Following the transaction, the insider now owns 2,996,766 shares in the company, valued at $249,061,222.26. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 666,819 shares of company stock worth $52,303,086. 1.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.